Semaglutide

Read 1. Eight explicitly identified men aged 45–60 were coded, with reports describing weight loss ranging from early treatment changes to substantial reductions over many months. Three were classified positive and five mixed because several reported gastrointestinal effects, nausea, muscle loss, pain, or other concerns alongside weight reduction. Among all 13 selected users, weight loss was the dominant outcome, with additional reports of appetite suppression and improved blood-sugar control. A 57-year-old man described 35 pounds lost over 15 weeks, while a 53-year-old reported meaningful weight loss but also substantial loss of muscle and strength after approximately 15 months. Effects commonly emerged within the first weeks, while longer-term accounts included weight plateaus, maintenance after stopping, and a switch prompted by supply difficulties. This is the strongest age-specific sample of the batch, but it remains a small, nonrandom subset of the far larger Reddit discussion.

Read 2. One man aged 45–60: a 57M on Ozempic for 15 weeks reported health and weight benefits, though appetite suppression was wearing off over the last 4–5 weeks. Everyone (n=14, heavily female, including women in their late 40s and 50s): 12 positive, 2 unclear — effortless appetite reduction, no more "food noise" or binge urges, steady loss of 1–4 lb a week at 0.5–2.4 mg weekly; women also reported relief of perimenopausal hip pain, brain fog and sleep problems. Side effects mild: injection-day nausea and constipation.

Note 1. The coded reports include Wegovy and Ozempic but not tirzepatide-only accounts. A former Ozempic user switching to Mounjaro was counted for the earlier semaglutide period only; switching because of shortages was classified supply_quality. Oral medications other than semaglutide were not substituted. A search hit about Foundayo was excluded after identifying it as a different active drug. Muscle loss is reported as an observation, not proof of a drug-specific mechanism. The selected sample is not representative of all semaglutide users, and the very large comment threads were not exhaustively coded.

Note 2. A 48-year-old who did not state sex was counted in everyone only. Several threads targeted older women, skewing the sample female.

Each read counted people independently. Overlap between the two reads is estimated from shared threads and removed; counts are approximate. How we count.